M&As this week: Thermo Fisher Scientific, Heptares Therapeutics


Thermo Fisher Scientific has announced its decision to acquire MTI-GlobalStem. Pursuant to the acquisition, MTI-GlobalStem will be merged into Thermo Fisher’s life sciences solution segment.

"Heptares Therapeutics has announced it will acquire G7 Therapeutics for a purchase consideration of $11.83m."

The acquisition will allow Thermo Fisher to expand its presence in biosciences and develop advanced research products to accelerate drug discovery using cell models.

Heptares Therapeutics has announced it will acquire G7 Therapeutics for a purchase consideration of $11.83m.

Heptares will be renamed as Zurich and G7 Therapeutics will be its wholly owned subsidiary, following the completion of the acquisition.

The acquisition will help Heptares to further expand and strengthen its G protein-coupled receptors platform for structure-based drug designing and development.


Image: Thermo Fisher Scientific has announced its decision to acquire MTI-GlobalStem. Photo: Courtesy of Coolcaesar at en.wikipedia.